Portola Pharmaceuticals (PTLA) Rating Increased to Sell at BidaskClub

Portola Pharmaceuticals (NASDAQ:PTLA) was upgraded by research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued on Wednesday.

A number of other equities analysts have also recently issued reports on PTLA. William Blair restated a “buy” rating on shares of Portola Pharmaceuticals in a report on Wednesday, September 12th. Oppenheimer set a $60.00 target price on Portola Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, September 20th. ValuEngine cut Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, October 6th. Zacks Investment Research upgraded Portola Pharmaceuticals from a “hold” rating to a “buy” rating and set a $27.00 target price on the stock in a report on Thursday, October 11th. Finally, Morgan Stanley lowered their price target on Portola Pharmaceuticals from $34.00 to $32.00 and set an “equal weight” rating on the stock in a report on Thursday, October 11th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $37.50.

Shares of NASDAQ PTLA opened at $23.17 on Wednesday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 6.51 and a current ratio of 6.61. The firm has a market capitalization of $1.51 billion, a P/E ratio of -4.82 and a beta of 1.89. Portola Pharmaceuticals has a 52-week low of $14.81 and a 52-week high of $55.48.



Portola Pharmaceuticals (NASDAQ:PTLA) last issued its earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($1.08) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.54) by $0.46. The business had revenue of $14.20 million for the quarter, compared to analysts’ expectations of $7.10 million. Portola Pharmaceuticals had a negative return on equity of 135.08% and a negative net margin of 1,020.52%. The company’s quarterly revenue was up 270.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.41) EPS. As a group, research analysts expect that Portola Pharmaceuticals will post -5.03 EPS for the current fiscal year.

In other news, Director Charles J. Homcy sold 64,218 shares of Portola Pharmaceuticals stock in a transaction on Monday, December 17th. The stock was sold at an average price of $18.61, for a total transaction of $1,195,096.98. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 4.60% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BB&T Securities LLC acquired a new stake in Portola Pharmaceuticals during the second quarter valued at $201,000. Oppenheimer Asset Management Inc. acquired a new stake in shares of Portola Pharmaceuticals in the second quarter worth about $230,000. Smith Asset Management Group LP lifted its position in shares of Portola Pharmaceuticals by 51.1% in the third quarter. Smith Asset Management Group LP now owns 8,100 shares of the biopharmaceutical company’s stock worth $216,000 after buying an additional 2,740 shares during the last quarter. Pacer Advisors Inc. acquired a new stake in shares of Portola Pharmaceuticals in the third quarter worth about $221,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Portola Pharmaceuticals in the second quarter worth about $484,000.

Portola Pharmaceuticals Company Profile

Portola Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics that could advance the fields of thrombosis and other hematologic diseases. The company's two FDA-approved medicines are Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo), an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness.

Featured Story: Price to Earnings Ratio (PE), For Valuing Stocks

Analyst Recommendations for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply